Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4678272 | 0.89 | PARP10 (0.46) | PARP10PARP15PARP2FFAR4KAT6A | |
| SCHEMBL17050498 | 0.89 | PARP15 (0.40) | PARP10PARP15PARP2ACACBACACA | |
| SCHEMBL4734966 | 0.78 | PARP10 (0.40) | PARP10PARP15PARP2FFAR4TRPV4 | |
| SCHEMBL4678875 | 0.78 | NQO1 (0.34) | PARP10FFAR4KAT6A | |
| SCHEMBL17609427 | 0.76 | PARP10 (0.42) | PARP10PARP15PARP2FFAR4ACACA | |
| SCHEMBL17050500 | 0.76 | PARP15 (0.37) | PARP10PARP15PARP2F2 | |
| SCHEMBL22657649 | 0.76 | PARP10 (0.42) | PARP10PARP15PARP2FFAR4KAT6A | |
| SCHEMBL4678195 | 0.75 | HTT (0.36) | — | |
| SCHEMBL19834574 | 0.74 | ACACA (0.56) | PARP10PARP15FFAR4ACACBACACA | |
| SCHEMBL19874193 | 0.74 | PARP10 (0.51) | PARP10PARP15PARP2FFAR4TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | PARP10 1616/4885PARP15 929/4885PARP2 1495/4885 |
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | PARP10 1616/4885PARP15 929/4885PARP2 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.